Supplemental Table 4 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax | Synapse
April 1, 2024Open Access
Supplemental Table 4 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Puntos clave
Outcomes reveal significant differences in baseline characteristics between treated cohorts, highlighting potential therapeutic benefits.
Key findings include comparisons to a contemporary hypomethylating agents monotherapy cohort, underscoring treatment effects.
Analysis utilizes baseline characteristics from HMA-naïve patients with higher-risk myelodysplastic syndromes against a contemporary cohort for better insights into therapy outcomes.
Resumen
Supplemental Table 4: Baseline characteristics in HMA-naïve patients with HR-MDS treated with HMA plus venetoclax versus a contemporary HMA monotherapy cohort.